vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and Expion360 Inc. (XPON). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $2.2M, roughly 1.1× Expion360 Inc.). Expion360 Inc. runs the higher net margin — -199.9% vs -265.2%, a 65.3% gap on every dollar of revenue. Over the past eight quarters, Expion360 Inc.'s revenue compounded faster (51.1% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Expion360 Inc. is a provider of high-performance lithium iron phosphate (LFP) battery solutions and supporting energy storage products. Its core customer segments cover recreational vehicle owners, marine users, off-grid lifestyle enthusiasts and residential users across the U.S. market, delivering safe, durable and low-carbon energy storage options.
BOLT vs XPON — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $2.2M |
| Net Profit | $-6.6M | $-4.4M |
| Gross Margin | — | -14.8% |
| Operating Margin | -283.4% | -234.4% |
| Net Margin | -265.2% | -199.9% |
| Revenue YoY | — | 11.8% |
| Net Profit YoY | 58.4% | -1663.2% |
| EPS (diluted) | $-9.38 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $2.2M | ||
| Q3 25 | $2.2M | $2.4M | ||
| Q2 25 | $1.8M | $3.0M | ||
| Q1 25 | $1.2M | $2.0M | ||
| Q4 24 | $0 | $2.0M | ||
| Q3 24 | $1.1M | $1.4M | ||
| Q2 24 | $1.3M | $1.3M | ||
| Q1 24 | $5.3M | $971.9K |
| Q4 25 | $-6.6M | $-4.4M | ||
| Q3 25 | $-7.1M | $722.8K | ||
| Q2 25 | $-8.6M | $-1.4M | ||
| Q1 25 | $-11.0M | $-1.2M | ||
| Q4 24 | $-15.9M | $-251.6K | ||
| Q3 24 | $-15.2M | $-8.8M | ||
| Q2 24 | $-21.2M | $-2.2M | ||
| Q1 24 | $-10.8M | $-2.2M |
| Q4 25 | — | -14.8% | ||
| Q3 25 | — | 22.7% | ||
| Q2 25 | — | 20.8% | ||
| Q1 25 | — | 24.5% | ||
| Q4 24 | — | 22.1% | ||
| Q3 24 | — | 12.1% | ||
| Q2 24 | — | 25.5% | ||
| Q1 24 | — | 22.9% |
| Q4 25 | -283.4% | -234.4% | ||
| Q3 25 | -355.1% | -125.4% | ||
| Q2 25 | -510.5% | -45.2% | ||
| Q1 25 | -991.4% | -56.0% | ||
| Q4 24 | — | -59.5% | ||
| Q3 24 | -1441.1% | -138.7% | ||
| Q2 24 | -1772.3% | -131.4% | ||
| Q1 24 | -324.1% | -202.4% |
| Q4 25 | -265.2% | -199.9% | ||
| Q3 25 | -329.4% | 30.2% | ||
| Q2 25 | -474.6% | -45.8% | ||
| Q1 25 | -903.4% | -56.2% | ||
| Q4 24 | — | -12.7% | ||
| Q3 24 | -1330.1% | -634.4% | ||
| Q2 24 | -1662.4% | -173.7% | ||
| Q1 24 | -205.0% | -225.6% |
| Q4 25 | $-9.38 | $-0.45 | ||
| Q3 25 | $-3.72 | $0.10 | ||
| Q2 25 | $-4.46 | $-0.41 | ||
| Q1 25 | $-0.29 | $-0.37 | ||
| Q4 24 | $-13.73 | $65.02 | ||
| Q3 24 | $-7.93 | $-24.55 | ||
| Q2 24 | $-11.12 | $-30.20 | ||
| Q1 24 | $-0.28 | $-31.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $3.0M |
| Total DebtLower is stronger | — | $197.2K |
| Stockholders' EquityBook value | $26.5M | $6.5M |
| Total Assets | $56.7M | $8.1M |
| Debt / EquityLower = less leverage | — | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $3.0M | ||
| Q3 25 | $31.9M | $4.3M | ||
| Q2 25 | $34.8M | $684.9K | ||
| Q1 25 | $38.8M | $1.1M | ||
| Q4 24 | $47.3M | $547.6K | ||
| Q3 24 | $53.8M | $3.3M | ||
| Q2 24 | $73.7M | $902.3K | ||
| Q1 24 | $91.3M | $2.3M |
| Q4 25 | — | $197.2K | ||
| Q3 25 | — | $205.6K | ||
| Q2 25 | — | $213.6K | ||
| Q1 25 | — | $221.8K | ||
| Q4 24 | — | $230.2K | ||
| Q3 24 | — | $239.9K | ||
| Q2 24 | — | $247.7K | ||
| Q1 24 | — | $255.4K |
| Q4 25 | $26.5M | $6.5M | ||
| Q3 25 | $32.1M | $9.0M | ||
| Q2 25 | $38.8M | $2.1M | ||
| Q1 25 | $46.8M | $3.2M | ||
| Q4 24 | $57.2M | $2.5M | ||
| Q3 24 | $72.0M | $2.5M | ||
| Q2 24 | $85.9M | $2.5M | ||
| Q1 24 | $104.2M | $3.7M |
| Q4 25 | $56.7M | $8.1M | ||
| Q3 25 | $65.1M | $10.7M | ||
| Q2 25 | $75.5M | $8.6M | ||
| Q1 25 | $85.9M | $9.2M | ||
| Q4 24 | $99.6M | $9.1M | ||
| Q3 24 | $109.3M | $10.1M | ||
| Q2 24 | $124.2M | $8.8M | ||
| Q1 24 | $142.9M | $10.0M |
| Q4 25 | — | 0.03× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.10× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.09× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | — | 0.10× | ||
| Q1 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-2.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-2.4M | ||
| Q3 25 | $-9.7M | $-2.1M | ||
| Q2 25 | $-9.6M | $-401.0K | ||
| Q1 25 | $-13.4M | $-1.2M | ||
| Q4 24 | $-14.4M | $-2.9M | ||
| Q3 24 | $-14.0M | $-3.2M | ||
| Q2 24 | $-16.1M | $-1.7M | ||
| Q1 24 | $-16.8M | $-1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -173.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | -2.90× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
